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Poster Session-I 71transplant consolidation strategies such as tandem transplantation
and maintenance therapies are usually taken at the time of this eval-
uation. It is not clear how often patients continue to have a drop in
their M protein after day 100 in the absence of additional therapy.
Methods: From among patients who underwent SCT for mye-
loma, we retrieved the day 100 (71–130 days) post-transplant para-
protein results and compared those values to the lowest subsequent
values reached prior to any additional therapy. There were 526 pa-
tients with serum or urine monoclonal protein studies available
from the day 71–130 time period after SCT and were considered
for the study.
Results: There were 338 patients who had an M protein that was
quantified on their serum or urine protein electrophoresis during the
day 100 evaluation. Of these, 199 patients (59%) had further reduction
of the M protein after day 100. Although these patients had a longer
time to progression compared to those with no further decrease after
day 100 (19.1 mos vs. 16.3 mos; P 5 0.009), there was no differences
in theoverall survival post transplant.Among 526 patients in whom a se-
rum or urine immunofixation result was available at the day 100 evalu-
ation, 66 (13%) were negative for both. Among the remaining 460
patients, 101 patients (22%) subsequent to the d100 evaluation became
immunofixation negative in serum and urine. The delayed IFE negative
patients performed as well as their early IFE negative counterparts, i.e.
a superior time to progression and overall survival from transplantation
Conclusions: Continued paraprotein responses (decrease in se-
rum or urine M protein or conversion of immunofixation positive
to negative) are seen in 53% of patients with myeloma undergoing
single SCT beyond the first 4 months after SCT, including an immu-
nofixation negative state, which predicts for superior outcome. This
needs to taken into consideration, when assessing the impact of post
transplant interventions and when making clinical decisions regard-
ing use of additional therapies post SCT.192
SAFETY AND EFFICACY OF THE BUSULFAN, CYCLOPHOSPHAMIDE AND
ETOPOSIDE PREPARATIVE REGIMEN (BUCYE) FOR AUTOLOGOUS HEMA-
TOPOIETIC STEM CELL TRANSPLANT (AUTOHSCT) IN PATIENTS WITH
ADVANCED AGGRESSIVE NHL (AA-NHL) OVER THE AGE OF 60 YEARS
Borate, U., Vaughan, W. University of Alabama at Birmingham, Bir-
mingham, AL
High dose chemotherapy followed by autoHSCT is the standard of
care for suitable patients with AA-NHL after failure of primary ther-
apy. We have previously reported an improvement in overall survival
(OS) and progression-free survival (PFS) in patients with AA-NHL
treated with the BuCyE preparative regimen and autoHSCT when
pharmacokinetics directed IV Busulfan was substituted for oral Bu-
sulfan in this regimen. Since this improvement was predominantly
due to reduced regimen related toxicity, we increased the upper limit
of age eligibility from 60 years of age to 72 years. Between September
2003 and June 2008, 23 patients between the ages of 60 and 72 with
intermediate and high-risk aggressive NHL underwent autoHSCT
using the BuCyE regimen. Out of the 23 patients between the ages
of 60 and 72, 12 were male and 11 were female. The median age
was 64 with a minimum age of 61 and a maximum age of 72. 18 pa-
tients had diffuse large B cell lymphoma, 8 were transplanted after
their first relapse, 6 after their first complete remission (CR) and 2 af-
ter their second relapse. Two patients had mantle cell lymphoma and
were transplanted in their second CR. Two patients had follicular
lymphoma with aggressive transformation and were transplanted in
their second CR. One patient had Burkitt’s lymphoma and was trans-
planted in first relapse. Eight patients out of the 23 had relapses. Six of
the eight relapsed within a year of autoHSCT, the other two relapsed
at 18 months and 42 months respectively. Ten patients died, three
from regimen related toxicity, five from relapse, and two from other
causes. Twelve patients (52 %) are alive and disease free with follow
up from 3 to 63 months from date of transplant, with a median follow
up of 24 months. The projected long term disease free survival by the
Kaplan Meier life table analysis is 31%.The pharmacokinetics di-
rected IV Busulfan, Cyclophosphamide and Etoposide Preparative
Regimen for autoHSCT is a reasonable regimen to attempt long-
term survival in patients with Advanced Aggressive NHL (AA-
NHL) over the age of 60 years.193
NON-MYELOABLATIVE CONDITIONING AND ALLOGENEIC TRANSPLAN-
TATION FOR MULTIPLE MYELOMA
Osman, K., Elliott, B.,Mandeli, J., Scigliano, E., Ross-Dodds, V., Isola, L.,
Grosskreutz, C. The Mount Sinai Medical Center, New York, NY
Autologous stem cell transplantation (ASCT) increases survival in
multiple myeloma (MM) but is not curative. Allogeneic transplanta-
tion (alloSCT) carries a lower relapse risk, attributed to a graft-ver-
sus-myeloma effect, but a greater transplant-related mortality
(TRM). Nonmyeloablative (NMA) conditioning reduces trans-
plant-related toxicity. Our group previously reported on 90 patients
conditioned with total body irradiation (TBI), fludarabine, and an-
tithymocyte globulin (ATG). Results were encouraging when used
during first remission in low-risk patients, but less-so in advanced
or resistant disease. We performed a retrospective analysis of 20 pre-
viously-treated MM patients who underwent NMA alloSCT from
2000–06. The median age was 52.5 (37.2–68.0) years. Twenty per-
cent had ISS stage 2 or 3 disease, and 25% had poor cytogenetics.
Seventeen patients received one or more ASCTs, but eleven still
had active disease prior to alloSCT. Fourteen allo-recipients had
matched-related and six had matched-unrelated donors. Median
time from diagnosis to alloSCT was 22.9 (12.2–139.6) months. Pa-
tients underwent conditioning with ATG plus fludarabine for 4
days and 1 dose of TBI. All received immunosuppression and antimi-
crobial prophylaxis. Patients were followed for a median of 40.5 (0.6–
91.1) months. Median time to engraftment (ANC. 500) was 5 days.
At day 100, 50% had achieved CR, disease-related mortality was
15%, and TRM 10%. Median OS was 21 (0.6–92) months and pro-
gression-free survival (PFS) 6.6 (0.6–92) months. Both 3-year OS
and 2-year PFS were 24%. OS survival was significantly greater for
patients younger than 52 years of age (27 vs. 8 mo, p 5 0.03), and
there was a trend toward greater OS for those with beta-2 microglo-
bulin less than 2.5 mg/l (27 vs. 8 mo, p 5 0.08). Donor type and Ig
type had no significant effect on survival. Our case series suggests
benefit of NMA alloSCT in refractory MM. Randomized trials
must be performed to confirm and further qualify this benefit.194
AN ANALYSIS OF THE CHARGES ASSOCIATED WITH PERIPHERAL BLOOD
HEMATOPOIETIC PROGENITOR CELL (HPC) MOBILIZATION, COLLEC-
TION AND CRYOPRESERVATION IN PATIENTS WITH LYMPHOMAS UN-
DERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
Walters, K.H., Hosing, C., Smith, V.R., Rhodes, B.A., Thompson, R.C.,
Qazilbash, M.H., McMannis, J.D., Alousi, A., De Lima, M.,
Kebriaei, P., Giralt, S., Khouri, I., Champlin, R.E., Popat, U.R. The Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX
Introduction: HPC may be mobilized with cytokines alone or
with chemotherapy followed by cytokines. The HPC yield is higher
and the failure rate is lower with chemo mobilization. Although a cell
dose of 2m CD341 cells/kg is considered adequate, some authors
have shown patients (pts) who receive\5m CD 341 cells /kg have
higher resource utilization post transplant. This study was to analyze
the costs associated with HPC chemo mobilization.
Patients and Methods: 149 pts with non-Hodgkin’s (n 5 101)
and Hodgkin’s (n 5 48) lymphomas who underwent HPC chemo-
mobilization from 1/03 and 12/04 were analyzed. Patients who col-
lected\2m CD341 cells /kg in 4 leukapheresis procedures were
called failures. Estimated costs were divided into preapheresis,aphe-
resis, and postapheresis costs.
Results: 133 pts underwent chemo mobilization. Chemotherapy
regimen was ifosfamide, etoposide, G-CSF, 6 rituximab in 98
(74%) pts. The average inpatient stay was 6 days (3–28). 24 pts re-
quired readmission for chemotherapy complications, median of 5
days (1–12). Patients received G-CSF for a median of 14 days (6–
34). Average number of days on oral antibiotics was 9 (0–16). For
successful mobilizers, the median number of apheresis procedures
required to reach target HPC dose of 5m CD341 cells/kg was 2
(1–7). 30 pts failed to collect adequate HPC on the 1st attempt. Of
those, 12 pts underwent a BM harvest ($2389/harvest), 4 were remo-
bilized with chemotherapy (1 mobilized successfully), 4 pts under-
went an allogeneic transplant ($250k–$500k/transplant) and 3 pts
underwent an autologous transplant with suboptimal cell dose (all
had prolonged time to engraftment and 1 pt required an allogeneic
72 Poster Session-Itransplant for graft failure). Average pre apheresis costs per patient
were $1800 (clinic visit, laboratory evaluation, central venous cathe-
ter insertion, and chest x-ray to check placement). The average costs
of chemotherapy administration, hospitalization, prophylactic anti-
biotics and G-CSF were $29181 (not including rituximab). This
does not include supportive care, I/V fluids, readmission costs or
professional fees. Post apheresis costs were $2493.
Conclusions: Interventions or newer agents that reduce the fail-
ure rate or the number of apheresis procedures required to reach
a target HPC dose without increasing the toxicity may reduce total
transplant costs.The financial implication for transplant centers
where reimbursement is DRG (diagnosis related group) or case
rate based is significant.
Estimated Chemo Mobilization Costs
National Hospital Median Estimated Total
Cost Item Average Cost (USD) (Range) Costs (USD)Daily room charge
for chemo
administration$863 6 (3–28) $5,178Ifosfamide 3.33 g/m2/d
x 3 d$372.87/gram 19.38g $7,227Etoposide 150mg/m2
 6 d$17.61/10mg 1,746mg $3,074Daily CBC, diff $93 5 (3–28) $465
Readmission, daily
room charge
(n524)$863 5 (1–12) $4,315Blood transfusions
(n564)$494 1.4 (0–6) $692Platelet transfusions
(n564)$494 1.5 (0–7) $741Oral antibiotics 9 (0–16) $104
Apheresis procedure $1,917.73 2 (1–7) $3,835
PB CD341 analysis $135 2 (estimated) $270
Total (without rituximab) $36,454Source: Cleverly and Associates; www.drugstore.com; Redbooke;
Thompson PDR.195
SALVAGE AND HEMATOPOIETIC RECOVERY WITH BORTEZOMIB AND
MELPHALAN IN CYTOPENIC RECURRENT AND REFRACTORY MULTIPLE
MYELOMA
Mazumder, A., Vesole, D., Jagannath, S. St. Vincents Cancer Center,
New York, NY
The management of relapsed and refractory multiple myeloma
(RRMM) remains difficult. Patients have short response duration,
become cytopenic and are not eligible for clinical trials of promising
new drugs. They often have inadequate numbers of stem cells (\3
10(6) CD34/kg) remaining for a myeloablative transplant. Thus, new
approaches are needed. We therefore initiated a pilot clinical trial to
enable the successful reconstitution of blood counts in patients with
RRMM so they could proceed onto new clinical trials and test the
synergy of bortezomib and melphalan clinically in non-myeloabla-
tive doses (stem cell boost). We have treated 9 patients with
RRMM who have failed novel agents (including bortezomib) and
chemotherapy (dexamethasone, cytoxan, etoposide, cisplatin, and
doxil) and who had only limited duration of response previously
with high dose melphalan. All patients were cytopenic (ANC \
1000 and/or platelets\ 50,000/ mcl) and thus not eligible for new
clinical trials. The melphalan was given at 30–50 mg/m2 on days 1
and 4, depending on the age and performance status of the patient.
Bortezomib at 1.3 mg/m2 was given on the same days after the mel-
phalan. The patients then received 1.5 to 2.2 10(6) CD34 cells/kg.
(depending upon the amount of remaining stem cells). We have seen
responses (.25%) in all 9, with.PR in 8 and VGPR in 1. More im-
portantly, all patients successfully engrafted WBC.2000 and plate-
lets.50,000/mcl. Duration of response was 2 months or greater and
all patients were able to proceed on to new clinical trials. All patients
were given treatment as outpatient and average duration of hospital-ization was 3 days (range 0 to 6) during cytopenia. Thus, the clinical
synergy between bortezomib and melphalan can lead to an effective
salvage strategy even for cytopenic patients with relapsed and refrac-
tory multiple myeloma. This non-myeloablative approach could
serve as a platform for proceeding on to new clinical trials for those
advanced patients without adequate numbers of stem cells for a -
myeloablative transplant.PEDIATRIC DISORDERS
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OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTSWITH PRIMARY AND SECONDARYMYELO-
DYSPLASTIC SYNDROMES
Parikh, S.H.1, Mendizabal, A.2, Betz-Stablein, B.2, Martin, P.L.1,
Szabolcs, P.1, Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2Emmes Corporation,
Rockville, MD
Myelodysplastic syndromes (MDS) respond poorly to chemother-
apy alone. Between 1995 and 2006, 23 pediatric patients with MDS
were transplanted with unrelated donor umbilical cord blood
(UCB) at our center. The median age was 11.09 yrs (range 1.11–
19.73); 20% of patients were male; median time from diagnosis to
transplant was 6.57 mo (range 2.00–61.37). Patients were followed
for a median of 5.3 yrs (range 1.64–12.36) post-transplant. MDS stage
was RA/RC 12 pts, RAEB 8 pts and RAEB-T 3 pts; 78.3% pts had pri-
mary MDS. Monosomy 7 was present in 17(74%) of patients. Patients
with frank AML were excluded. Preparative regimen was TBI based
in 18 (78%) pts and melphalan was used in 14 (61%) of patients.
GVHD prophylaxis consisted of CSA/steroids (19 pts) and CSA/
MMF (4 pts). Grafts were HLA matched at Class I (A and B) at low
resolution and Class II (DRB1) at the allelic level resulting in
16(70%) 4/6 and 7(30%) 5/6 matched transplants. The grafts con-
tained a median of 4.04 107 (range 1.68–12.58) total nucleated cells
(TNC)/kg pre-cryopreservation; 3.58  107 (range 1.01–12.00)
TNC/kg and 1.72 105 (range 0.17–28.46) CD341 cells/kg were in-
fused. Cumulative incidence of neutrophil engraftment (ANC.500/
mL) at days 42 & 100 was 73.9% (95% CI 55.1%–92.7%) and 91.3%
(95% CI 71.3%–100%), and that of platelet engraftment (50K) at 180
days was 69.6% (49.8%–89.4%). Three pts had graft failure while 3
pts (13%) engrafted slowly (after Day 42), perhaps related to some
underlying marrow dysfunction caused by MDS. Three patients de-
veloped acute GvHD grades II-IV with a cumulative incidence at 100
Days of 13% (95% CI 0.0%–27.1.0%). Four patients relapsed with
a CI of relapse at 3 yrs of 13.0% (95% CI 0.0%–27.1%). Cumulative
incidence of non-relapse mortality at 1 yr was 27% (95% CI 8.0%–
46.0%). Ten pts died: 3 graft failure, 4 relapse, 2 infections (1 adeno-
virus, 1 toxoplasmosis), and 1 EBV LPD. Overall survival probability
at 1 and 3 years were 69.6% (95% CI 46.6%–84.2%) and 59.2% (95%
CI 35.9%–76.5%) respectively. Event-free survival (EFS) probabili-
ties at 1 and 3 years were 69.6% (95% CI 46.6%–84.2%) and 60.9%
(38.3%–77.4%) respectively. Factors associated with better EFS
were age # 10 yrs (p 5 0.05) and weight # 38 kg (p 5 0.03). These
results, especially in younger pts with Monosomy 7 and MDS, are
equivalent to published matched allogeneic bone marrow data.
UCB should be actively considered for pediatric MDS pts lacking
matched related or unrelated adult donors.197
A PHASE I/II STUDY OF CYCLOPHOSPHAMIDE AND TOPOTECAN IN PA-
TIENTS WITH HIGH-RISK MALIGNANCIES UNDERGOING AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ST. JUDE LONG-
TERM FOLLOW-UP
Kasow, K.A.1, Barfield, R.C.2, Wright, N.L.1, Li, C.1, Srivastava, D.K.1,
Horwitz, E.M.3, Leung, W.1, Woodard, P.1, Bowman, L.C.1,
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